MarketCap
VistaGen Therapeutics VTGN
$ 0.19
-2.12%
Facebook
X
Telegram
VistaGen Therapeutics Market Cap | VTGN
As of October 22, 2026 VistaGen Therapeutics has a market cap of $ 7.23 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap VistaGen Therapeutics
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.7 M | 73.5 M | 73 M | 11.8 M | 11.7 M | 9.44 M | 19.3 M | 30.6 M | 13.9 M | 14.9 M | 15 M | 10.7 M | 10.5 M | 15.9 M | 36.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.5 M | 9.44 M | 24.6 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Syndax Pharmaceuticals
SNDX
|
1.73 B | $ 13.15 | -0.75 % | $ 1.14 B |  USA |
 |
Soligenix
SNGX
|
6.12 M | $ 0.35 | -1.27 % | $ 1.82 M | USA |
 |
Intellia Therapeutics
NTLA
|
776 M | $ 11.65 | -1.6 % | $ 1.26 B | USA |
 |
Nuvation Bio
NUVB
|
1.99 B | $ 4.85 | 1.89 % | $ 1.66 B | USA |
 |
Sarepta Therapeutics
SRPT
|
1.64 B | $ 18.56 | -3.18 % | $ 1.86 B | USA |
 |
Processa Pharmaceuticals
PCSA
|
4.14 M | $ 1.76 | 1.73 % | $ 2.3 M | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
24 B | $ 0.46 | -10.31 % | $ 5.67 B |  Israel |
 |
SELLAS Life Sciences Group
SLS
|
567 M | $ 12.14 | 1.34 % | $ 1.32 B | USA |
|
Protara Therapeutics
TARA
|
245 M | $ 2.5 | -2.34 % | $ 107 M | USA |
 |
Relay Therapeutics
RLAY
|
546 M | $ 18.41 | -0.22 % | $ 3.16 B | USA |
 |
Pfizer
PFE
|
155 B | $ 29.85 | -0.95 % | $ 170 B | USA |
 |
Supernus Pharmaceuticals
SUPN
|
3.11 B | $ 41.21 | -0.05 % | $ 2.33 B | USA |
 |
Takeda Pharmaceutical Company Limited
TAK
|
23.8 B | $ 19.93 | -0.75 % | $ 31.5 B |  Japan |
 |
Revolution Medicines
RVMD
|
19.6 B | $ 194.28 | -1.15 % | $ 36.9 B | USA |
 |
Rhythm Pharmaceuticals
RYTM
|
6.34 B | $ 88.62 | -1.75 % | $ 5.76 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
277 M | $ 3.65 | 3.4 % | $ 281 M | USA |
 |
Sana Biotechnology
SANA
|
995 M | $ 2.35 | -0.42 % | $ 595 M | USA |
 |
Zai Lab Limited
ZLAB
|
21.6 B | $ 24.2 | -3.51 % | $ 26.5 B |  China |
 |
Pulmatrix
PULM
|
5.08 B | $ 1.57 | 9.79 % | $ 5.73 B | USA |
 |
Zentalis Pharmaceuticals
ZNTL
|
192 M | $ 2.36 | -1.26 % | $ 170 M | USA |
 |
Zoetis
ZTS
|
56.1 B | $ 79.62 | -0.52 % | $ 35.3 B | USA |
 |
Ultragenyx Pharmaceutical
RARE
|
2.01 B | $ 15.92 | -0.62 % | $ 1.57 B | USA |
 |
XTL Biopharmaceuticals Ltd.
XTLB
|
855 M | $ 1.87 | -3.61 % | $ 1.26 B | Israel |
 |
Cleveland BioLabs, Inc.
CBLI
|
56.9 M | - | -7.31 % | $ 49 M | USA |
 |
AC Immune SA
ACIU
|
287 M | $ 2.47 | -0.8 % | $ 249 M |  Schweiz |
 |
Five Prime Therapeutics, Inc.
FPRX
|
616 M | - | - | $ 1.77 B | USA |
 |
Adagene
ADAG
|
224 M | $ 2.41 | -3.6 % | $ 142 M | China |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 4.11 | 7.59 % | $ 2.75 M | USA |
 |
ADC Therapeutics SA
ADCT
|
139 M | $ 1.5 | -1.32 % | $ 191 M | Schweiz |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 11.01 | -1.96 % | $ 2.62 B | USA |
 |
Assembly Biosciences
ASMB
|
308 M | $ 20.46 | -3.45 % | $ 229 M | USA |
 |
Allogene Therapeutics
ALLO
|
545 M | $ 1.33 | -0.38 % | $ 293 M | USA |
 |
Amgen
AMGN
|
198 B | $ 438.34 | -0.14 % | $ 236 B | USA |
 |
Ardelyx
ARDX
|
1.62 B | $ 3.13 | -2.49 % | $ 754 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
312 M | $ 3.06 | -4.38 % | $ 111 M | USA |
 |
Artelo Biosciences
ARTL
|
255 K | $ 2.56 | -2.29 % | $ 484 K | USA |
 |
Biofrontera AG
BFRA
|
220 M | - | -8.24 % | $ 105 M |  Germany |
 |
Bicycle Therapeutics plc
BCYC
|
351 M | $ 3.57 | -0.83 % | $ 247 M |  Britain |
 |
Catabasis Pharmaceuticals, Inc.
CATB
|
80.6 M | - | -6.97 % | $ 657 M | USA |
 |
Beam Therapeutics
BEAM
|
3.2 B | $ 24.84 | -0.36 % | $ 2.46 B | USA |
 |
China Biologic Products Holdings, Inc.
CBPO
|
4.56 B | - | 1.68 % | $ 4.65 B | China |
 |
Benitec Biopharma
BNTC
|
562 M | $ 8.5 | -5.97 % | $ 396 M | USA |
 |
BioNTech SE
BNTX
|
22 B | $ 91.29 | 0.13 % | $ 22.1 B | Germany |
 |
ANI Pharmaceuticals
ANIP
|
1.24 B | $ 72.24 | -0.59 % | $ 1.45 B | USA |
 |
C4 Therapeutics
CCCC
|
234 M | $ 3.17 | 0.32 % | $ 263 M | USA |
 |
Cerus Corporation
CERS
|
496 M | $ 2.39 | 3.46 % | $ 456 M | USA |
 |
Certara
CERT
|
1.08 B | $ 10.18 | 4.04 % | $ 1.63 B | USA |
 |
Flexion Therapeutics, Inc.
FLXN
|
521 M | - | - | $ 459 M | USA |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.02 | 2.0 % | $ 119 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 116.28 | -0.15 % | $ 12.1 B | USA |